Axovant Orphan Drug Designation

AXOVANT GENE THERAPIES RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR AXO-AAV-GM1 FOR THE TREATMENT OF GM1 GANGLIOSIDOSIS NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company...

AXOVANT PRESENTS FIRST EVIDENCE OF CLINICAL STABILIZATION

AXOVANT PRESENTS FIRST EVIDENCE OF CLINICAL STABILIZATION IN TAY-SACHS DISEASE AT THE EUROPEAN SOCIETY OF GENE AND CELL THERAPY 27TH ANNUAL CONGRESS Initial data with AXO-AAV-GM2 suggests stabilization of disease course, attainment of normal developmental milestones,...